Inulin: A New Adjuvant With Unknown Mode of Action  by Skwarczynski, Mariusz
EBioMedicine 15 (2017) 8–9
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryInulin: A New Adjuvant With Unknown Mode of ActionMariusz Skwarczynski, PhD, MSc (Eng)
School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, AustraliaDOI of original article: http://dx.doi.org/10.1016/j.ebio
E-mail address:m.skwarczynski@uq.edu.au.
http://dx.doi.org/10.1016/j.ebiom.2016.11.019
2352-3964/© 2016 The Author. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 11 November 2016
Accepted 11 November 2016
Available online 15 November 2016
hepatitis B,West Nile virus, Japanese encephalitis, human immunodeﬁ-
ciency virus, SARS, and anthrax, amongst others. The carbohydrate was
effective and safe in both experimental animals, as well as in humans.
Yet, despite the large number of studies performed, its mechanism of
action is still unclear. This prompted Ishii and coworkers to investigate
the potentialmode of action of inulinmicroparticles. At ﬁrst, they inves-Traditionally, vaccines have been produced using whole pathogen
cultures, and even today, many vaccines are based on attenuated or
killed microorganisms. However, such vaccines, while effective, have
signiﬁcant shortcomings. Not all pathogens can be easilymass produced
at the desired developmental stage (e.g.malaria sporozoites). Vaccines
may induce undesired immune responses, including strong allergic re-
actions and autoimmunity. Reversion to the virulent form, low-stability,
and problems associated with handling of dangerous species during
production are other potential drawbacks. Therefore, the use of small
antigens instead of whole organisms is becomingmore popular inmod-
ern vaccine development (Skwarczynski and Toth, 2016). Subunit-
based vaccines have a much better safety proﬁle and induce more spe-
ciﬁc and controlled immune responses. However, they typically lose
their danger signals - the microorganism elements recognizable by in-
nate immunity that initiate immune responses. To overcome the loss
of “activators of immunity”, immune stimulators (adjuvants) have
been introduced to many current vaccine formulations (Barclay and
Petrovsky, 2017). Adjuvants are usually recognized by pattern recogni-
tion receptors (PRRs), such as Toll-like receptors (TLRs) and C-type lec-
tin receptors displayed by antigen presenting cells (APCs). However,
many potent adjuvants (e.g. complete Freund's adjuvant) suffer from
signiﬁcant toxicity. Only a few adjuvants have been used in human vac-
cines, and all of them (except alum) are approved for one particular vac-
cine only. The limited choice of safe adjuvants has generated strong
interest in the development of new immune stimulating molecules
and/or vaccine delivery systems, as exempliﬁed by inulin, reported by
Ishii and coworkers in this issue of EBioMedicine (Hayashi et al., 2017).
Inulin (Advax™, β-D-[2→ 1] poly(fructo-furanosyl) α-D-glucose) is
a plant-derived carbohydrate. It has no immunological activity in solu-
ble form; however, once it is formulated into delta inulinmicroparticles,
its adjuvanting activity is widely acknowledged (Petrovsky and Cooper,m.2016.11.015.
. This is an open access article under2015). Inulin was applied to enhance vaccine efﬁcacy against inﬂuenza,
tigated its adjuvanting capacity when administered together with anti-
gens already bearing danger signals. It has been reported that inﬂuenza
split vaccine (SV) elicits Th2,whilewhole virion inﬂuenza vaccine (WV)
triggers a Th1 response. When antigens were delivered with inulin, im-
mune responses were signiﬁcantly increased and the Th1/Th2 direction
remained unchanged. Andwhen inulin was delivered with “danger sig-
nal free” ovalbumin as an antigen, nothing happened. No antibody pro-
duction against ovalbumin was detected. Moreover, inulin on its own
was not able to stimulate dendritic cell (DC) maturation in vitro. Matu-
ration of DCs is the crucial step before adaptive immunity can be activat-
ed. Just taking into account these observations, it might be assumed that
inulin acts as a delivery system, possibly by preventive antigen degrada-
tion or through improved delivery toAPCs, butwithout its own immune
stimulating abilities.
Is inulin really just a delivery platform for vaccines, without
adjuvanting properties? The answer is no. In contrast to in vitro testing,
in vivoDCmaturation experiments showed that inulin acted as an adju-
vant and enhanced the expression ofmaturationmarkers on these cells.
The reason for such unique behavior of inulin is yet to be determined. In
addition, Ishii and coworkers demonstrated that DCs and phagocytic
macrophages, as well as tumor necrosis factor (TNF)-α played a crucial
role in the adjuvanting ability of inulin. It is of note that the ability of in-
ulin to enhance adaptive immune responses when injected a day earlier
than an antigen was reported previously (Saade et al., 2013). Thus, inu-
lin acts as an unusual adjuvant, as it did not force the direction of im-
mune response (Th1 vs Th2), as typical adjuvants do. For example,
commercially-approved alum is a well-known Th-2 pathway stimula-
tor, while CpG-ODN triggers Th1 response (Azmi et al., 2014).
The article in focus brings us closer to understanding the way inulin
interacts with the immune system; however, further investigation is
still required to disclose its mechanism, or mechanisms, of action. As
soon as we understand how inulin interacts with the immune system,
we can start manipulating inulin. Once the mechanism(s) of action is
known, the carbohydrate molecule can be modiﬁed to improve its
adjuvanting capacity, antigen can be chemically incorporated into inu-
lin, and so on. Alternatively, the research order could be inverted, andthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
9M. Skwarczynski / EBioMedicine 15 (2017) 8–9modiﬁcations could bemade as ameans for deciphering themechanism
of action of inulin. Regardless of which approach proves most effective,
an understanding of inulin's mechanism of action will be crucial not
only in improving its efﬁcacy, but also in fully establishing its safety pro-
ﬁle, especially in immune impaired/dysregulated individuals, such as
the elderly.
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